ROCKAWAY, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2024, after the close of the market on Wednesday, November 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.
Wednesday, November 13, 4:30 PM EST
Dial-In: 877-407-8835 / +1 201-689-8779
Conference ID: 13744121
Webcast: electroCore Earnings Webcast
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$9.94 |
Daily Change: | -0.15 -1.49 |
Daily Volume: | 89,338 |
Market Cap: | US$64.110M |
November 13, 2024 September 10, 2024 August 07, 2024 August 01, 2024 June 25, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB